Many treatment guidelines for psoriasis rely heavily on body surface area (BSA) involvement to determine disease severity and eligibility for systemic therapies like biologics. Traditionally, patients with less than 10% BSA involvementespecially Topical Management of Plaque PsoriasisA Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation JCAD The Journal of Clinical and Aesthetic Dermatology Too often, BPC 157 gets boxed into a single use: injury recovery. Gabriel Alizaidy, MD, MS Targeted Oral Peptide Icotrokinra for Psoriasis Involving High Impact Sites NEJM Evidence BPC 157 Explained: Benefits, Safety & Oral vs Injectable Options